Back to search

Article

Practical biomarkers and robust multiplex models for the prediction of response to the promising first-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumors

2023-01-19

Abstract excerpt

<h4>Background: </h4> In advanced or metastatic ovarian cancer patients, the therapeutic impact of molecular targeted agents and immunotherapy is limited, and current chemotherapeutic algorithm is still far from personalized medicine. We recently demonstrated that intraperitoneal carboplatin with dose-dense paclitaxel (ddTCip) therapy is a promising front-line chemotherapy even in the patients with residual perito...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
761bd204-f9a9-52f6-95ab-eb97f0046353
DOI
10.21203/rs.3.rs-2490080/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Practical biomarkers and robust multiplex models for the prediction of response to the promising first-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumorsDOI 10.21203/rs.3.rs-2490080/v1
Practical biomarkers and robust multiplex models for the prediction of response to promising first-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumorsSemantic proximity
Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: Practical biomarkers and robust multiplex modelsSemantic proximity
Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian CancerSemantic proximity
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.Semantic proximity
Identification of platinum-resistance related small GTPase binding signatures to predict the prognosis of ovarian cancer by machine learning and integrated bioinformatic analysesSemantic proximity
Predicting Response to Platin Chemotherapy Agents with Biochemically-inspired Machine LearningSemantic proximity
Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinomaSemantic proximity
A Comprehensive Tumor Molecular Profile Analysis in Clinical Practice: A Single Center’s ExperienceSemantic proximity
Identification and Validation of a Novel Prognostic Model Based on Platinum Resistance-Related Genes in Bladder CancerSemantic proximity
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learningSemantic proximity
Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity
Robust identification of shared key genomic biomarkers for diagnosis and therapies of pancreatic cancer with type-2 diabetesSemantic proximity
Select a neighboring publication to make it the new centre.